Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioArctic ABLTS:0RV2 +1.66%72 Equity-to-Asset is 0.72 as of Jun. 2026, which is 15% below its 10-year median of 0.85. GuruFocus rates LTS:0RV2 with a GF Score™ of 72/100 and a GF Value™ of kr493.34 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, BioArctic AB ranks better than 54.54% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioArctic AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr2,016 Mil. BioArctic AB's Total Assets for the quarter that ended in Jun. 2026 was kr2,819 Mil.
Therefore, BioArctic AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.72.
The historical rank and industry rank for BioArctic AB's Equity-to-Asset or its related term are showing as below:
LTS:0RV2'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09 Med: 0.85 Max: 0.94
Current: 0.72
During the past 10 years, the highest Equity to Asset Ratio of BioArctic AB was 0.94. The lowest was 0.09. And the median was 0.85.
LTS:0RV2's Equity-to-Asset is ranked better than 54.54% of 1410
companies
in the Biotechnology industry
Industry Median: 0.69
vs LTS:0RV2: 0.72
BioArctic AB (LTS:0RV2) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioArctic AB Equity-to-Asset Related Terms
BioArctic AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioArctic AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RV2 vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, BioArctic AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioArctic AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioArctic AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioArctic AB (LTS:0RV2) has a Equity-to-Asset of 0.72 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioArctic AB and its competitors. This is 15% below median its historical median of 0.85. Over the past decade, BioArctic AB's Equity-to-Asset has ranged from 0.09 to 0.94. According to the industry distribution chart, BioArctic AB ranks #641 out of 1410 companies in the Biotechnology industry, placing it in the top 45.5%.
Is BioArctic AB's Equity-to-Asset too high?
BioArctic AB's current Equity-to-Asset of 0.72 is 15% below median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.94. The Biotechnology industry median Equity-to-Asset is 0.69. BioArctic AB's value of 0.72 is 4.3% above this industry median. Based on the distribution chart, BioArctic AB ranks #641 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioArctic AB has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #641 out of 1410 companies for Equity-to-Asset. This puts BioArctic AB in the upper half of its industry. The industry median Equity-to-Asset is 0.69. BioArctic AB's value of 0.72 is 4.3% above this benchmark. Historically, BioArctic AB's own Equity-to-Asset has ranged from 0.09 to 0.94 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.69, BioArctic AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioArctic AB's current Equity-to-Asset of 0.72 is 4.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioArctic AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioArctic AB's current Equity-to-Asset is 0.72, which is 15% below median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (LTS:0RV2) is currently considered Possible Value Trap. The stock's GF Value™ is kr493.34, compared to a current price of kr324.00 — trading 34.3% below its estimated fair value. The current Equity-to-Asset is 0.72, which is 15% below median its 10-year median of 0.85 and 4.3% above the Biotechnology industry median of 0.69. BioArctic AB's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioArctic AB (LTS:0RV2), the current Equity-to-Asset is 0.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (LTS:0RV2) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of kr324.00 is trading 34.3% below its estimated GF Value™ of kr493.34.
GuruFocus considers BioArctic AB to be Possible Value Trap.
Key valuation signals for LTS:0RV2:
Equity-to-Asset: 0.72 (15% below median its 10-year median of 0.85)
GF Value™: kr493.34 vs. price of kr324.00 (34.3% below fair value)
Industry Position: 4.3% above the Biotechnology median (#641 of 1410)
No single metric tells the full story. See the LTS:0RV2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
72GF Score
Get the complete analysis for LTS:0RV2
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RV2 has been successfully added to your 
